Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus uninterrupted vitamin K antagonist during catheter ablation for atrial fibrillation
2012-001484-79Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Incidence of post-procedure major bleeding events. Started Oct 2012; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2012-001484-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001484-79.